ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 237 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 846,953 | $20,284,524 | 7.02% |
| Baker Brothers Advisors | 42,864,612 | $1,026,607,457 | 5.94% |
| Palo Alto Investors LP | 2,405,793 | $57,618,742 | 4.66% |
| Birchview Capital, LP | 249,400 | $5,973,130 | 4.48% |
| RTW INVESTMENTS, LP | 9,783,249 | $234,308,814 | 4.46% |
| EcoR1 Capital, LLC | 5,991,479 | $143,495,922 | 3.52% |
| EMERALD ADVISERS, LLC | 1,616,952 | $38,726,000 | 1.69% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,291,094 | $30,921,701 | 1.68% |
| Opaleye Management Inc. | 217,000 | $5,197,150 | 1.24% |
| Frazier Life Sciences Management, L.P. | 857,338 | $20,533,245 | 1.23% |
| RICE HALL JAMES & ASSOCIATES, LLC | 886,453 | $21,230,559 | 1.20% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 151,000 | $3,616,450 | 1.10% |
| SECTOR GAMMA AS | 200,696 | $4,806,669 | 1.08% |
| AlphaCentric Advisors LLC | 50,000 | $1,197,500 | 0.66% |
| Capital Impact Advisors, LLC | 19,372 | $463,959 | 0.51% |
| CROWN ADVISORS MANAGEMENT, INC. | 30,000 | $718 | 0.47% |
| Neo Ivy Capital Management | 36,483 | $874 | 0.46% |
| Nan Fung Group Holdings Ltd | 29,984 | $718,117 | 0.46% |
| Jackson Creek Investment Advisors LLC | 47,395 | $1,135 | 0.45% |
| Penn Capital Management Company, LLC | 187,003 | $4,478,722 | 0.44% |
External links
This page lists ACADIA PHARMACEUTICALS INC's shareholders in Q2 2023. To view ACADIA PHARMACEUTICALS INC's shareholder history, click here.